

Aden Ka-Yin Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2001173/publications.pdf>

Version: 2024-02-01

31
papers

1,223
citations

393982

19
h-index

414034

32
g-index

32
all docs

32
docs citations

32
times ranked

2294
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	0.8	232
2	Adult IDH wild-type lower-grade gliomas should be further stratified. <i>Neuro-Oncology</i> , 2017, 19, 1327-1337.	0.6	177
3	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. <i>Modern Pathology</i> , 2015, 28, 177-186.	2.9	107
4	IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. <i>Brain Pathology</i> , 2020, 30, 541-553.	2.1	73
5	Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. <i>Modern Pathology</i> , 2014, 27, 332-342.	2.9	45
6	Biomarker-based prognostic stratification of young adult glioblastoma. <i>Oncotarget</i> , 2016, 7, 5030-5041.	0.8	45
7	TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroupsâ€”A meta-analysis of aggregate data. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 1-9.	2.0	44
8	Combination genetic signature stratifies lower-grade gliomas better than histological grade. <i>Oncotarget</i> , 2015, 6, 20885-20901.	0.8	42
9	FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p. <i>Oncogene</i> , 2019, 38, 33-46.	2.6	41
10	<sc>MIR</sc>â€137 Suppresses Growth and Invasion, is Downregulated in Oligodendroglial Tumors and Targets <sc>CSE1L</sc>. <i>Brain Pathology</i> , 2013, 23, 426-439.	2.1	39
11	SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis. <i>Oncogene</i> , 2018, 37, 1159-1174.	2.6	36
12	Pediatric low-grade gliomas can be molecularly stratified for risk. <i>Acta Neuropathologica</i> , 2018, 136, 641-655.	3.9	36
13	TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. <i>Oncotarget</i> , 2015, 6, 24871-24883.	0.8	34
14	Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. <i>Laboratory Investigation</i> , 2018, 98, 968-976.	1.7	33
15	Clinical and mutational profiles of adult medulloblastoma groups. <i>Acta Neuropathologica Communications</i> , 2020, 8, 191.	2.4	30
16	Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival. <i>PLoS ONE</i> , 2013, 8, e67421.	1.1	25
17	The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. <i>Laboratory Investigation</i> , 2017, 97, 946-961.	1.7	24
18	Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 8627-36.	0.5	24

#	ARTICLE	IF	CITATIONS
19	Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. <i>Oncotarget</i> , 2016, 7, 64615-64630.	0.8	22
20	Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz015.	0.4	22
21	Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. <i>Modern Pathology</i> , 2021, 34, 1245-1260.	2.9	21
22	<i>TP53</i> and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2016, 375, 2206-2208.	13.9	16
23	STK3 promotes gastric carcinogenesis by activating Ras-MAPK mediated cell cycle progression and serves as an independent prognostic biomarker. <i>Molecular Cancer</i> , 2021, 20, 147.	7.9	13
24	Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas. <i>Neuro-Oncology</i> , 2017, 19, 1008-1010.	0.6	12
25	TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 11485-94.	0.5	11
26	Establishment and characterization of meningioma patient-derived organoid. <i>Journal of Clinical Neuroscience</i> , 2021, 94, 192-199.	0.8	9
27	Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication. <i>Frontiers in Oncology</i> , 2022, 12, 839302.	1.3	3
28	Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals. <i>Journal of Neuro-Oncology</i> , 2018, 139, 307-322.	1.4	2
29	Low-grade BRAF V600E mutant oligodendroglioma-like tumors of children may show EGFR and MET amplification. <i>Brain Pathology</i> , 2021, 31, 211-214.	2.1	2
30	HG-07ABERRANTLY EXPRESSED microRNAs IN BRAF MUTATED YOUNG ADULT GBM. <i>Neuro-Oncology</i> , 2016, 18, iii49.2-iii49.	0.6	1
31	Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106882.	0.6	1